Clinical Study Notes: Unipolar and Bipolar Mood Disorders
Part 1: Unipolar Mood Disorders
1. Systemic Biological Impact & Screening
Multi-Factorial Etiology: Unipolar depression is a biopsychosociocultural condition affecting mind, body, and spirit.
Pro-Inflammatory State: Both depression and anxiety are pro-inflammatory states. Anxiety additionally increases sympathetic nervous system (SNS) activity.
Cardiovascular & Medical Comorbidities:
Depression significantly increases risks of cardiovascular disease (CVD), myocardial infarction (MI), stroke (CVA), and diabetes progression.
Post-MI depression increases -year mortality risk and elevates post-heart attack stroke risk by .
Diagnostic & Screening Assessment:
Biomarkers: No universal diagnostic blood tests or biomarkers currently exist; diagnosis relies on clinical assessment, Mental Status Examination (MSE), and ruling out physiological mimics (e.g., hypothyroidism via TSH, chronic fatigue syndrome, CBC with differential).
Measurement-Based Care (MBC): Utilizes self-report Measurement-Based Questionnaires (MBQs) such as the PHQ-9 (new standard for MDD), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale (ZDRS), and Geriatric Depression Scale (GDS).
Universal screening is recommended for ages and all depressed individuals must be screened for suicide risk.
2. Clinical Subtypes & Diagnostic Criteria
Major Depressive Disorder (MDD):
Threshold: Requires symptoms present for most of the day, nearly every day, for at least .
Core Criteria: Must include either Depressed Mood (Dysphoria) or Anhedonia (loss of interest or pleasure).
Additional Symptoms: Appetite or weight changes ( body weight change), sleep disturbances, low energy/fatigue, psychomotor agitation (PMA) or retardation (PMR), poor concentration/decision-making, worthlessness or inappropriate guilt, and suicidal ideation (SI).
Dysthymia (Persistent Depressive Disorder):
Chronic mild-to-moderate depression present of the time for without remission.
Requires symptoms (appetite changes, sleep issues, fatigue, low self-esteem, poor concentration, hopelessness) without a Major Depressive Episode in the first .
Disruptive Mood Dysregulation Disorder (DMDD):
Pediatric diagnosis (ages , onset before age ) featuring severe, recurrent temper outbursts ( for ) with persistent anger and irritability between outbursts.
Other Depressive Subtypes:
Postpartum Depression: Frequently presents with severe anxiety regarding infant well-being.
Seasonal Affective Disorder (SAD): Linked to seasonal light reduction; managed with phototherapy and Omega-3 fatty acids (pure EPA).
Adjustment Disorder with Depressed Mood: Short-term depressive response to an identifiable life stressor.
Premenstrual Dysphoric Disorder (PMDD), Psychotic Depression, Substance-Induced Mood Disorder.
3. Epidemiology & High-Risk Populations
Gender Differences: Women experience MDD at a ratio compared to men ( lifetime prevalence). Men have a higher completed suicide rate, primarily utilizing firearms.
Pediatric & Adolescent Populations:
experience a Major Depressive Episode before age . Suicide is a leading cause of death in ages . Past history of self-harm is the single strongest predictor of suicide worldwide.
Older Adults:
Highest completed suicide rate occurs among Caucasian males age .
Late-life depression can manifest as "Pseudo-Dementia" (cognitive deficits secondary to depression) and is an independent risk factor for dementia.
High-Stress & Vulnerable Groups: Populations experiencing chronic social or minority stress experience heightened psychiatric burden and health disparities.
4. Interventions & Pharmacological Management
Levels of Prevention:
Primary: Focuses on community resilience, parental support, wellness, exercise, and health education.
Secondary: Screen and intervene using MBQ tools (e.g., PHQ-9), early psychotherapy (CBT, IPT), and medication initiation.
Tertiary: Advanced therapies for chronic cases, including Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), and Deep Brain Stimulation (DBS).
Antidepressant Considerations:
Suicide Risk Window: During weeks of antidepressant initiation, increased physical energy and motivation precede mood elevation, creating a window of heightened risk to execute a suicide plan.
End-of-Life / Palliative Care: Psychostimulants (e.g., Methylphenidate) are the treatment of choice due to rapid onset of action when time constraints preclude traditional antidepressants.
MAOIs: Require strict dietary avoidance of tyramine-rich foods (aged cheeses, organ meats, fermented foods, wine/beer) to prevent life-threatening hypertensive crisis.
Part 2: Bipolar Spectrum Disorders
1. Categorization & Episode Characteristics
Bipolar Spectrum Classifications:
Bipolar I Disorder (BAD-I): Characterized by Manic Episode or Mixed Episode ( of simultaneous mania and MDD). Major Depressive Episodes frequently occur but are not strictly required.
Bipolar II Disorder (BAD-II): Characterized by Hypomanic Episode Major Depressive Episode. Full manic episodes never occur.
Cyclothymic Disorder: Chronic mood instability lasting with alternating hypomanic and dysthymic symptoms without full MDE or Mania.
Rapid Cycling Specifier: Defined as mood episodes (mania or hypomania) within a single year.
Clinical Phases:
Manic Episode: Abnormally elevated, expansive, or euphoric mood for with symptoms (or irritable mood with symptoms): grandiosity, decreased need for sleep (), pressured speech, flight of ideas, distractibility, increased goal-directed activity, and reckless impulsivity.
Hypomanic Episode: Elevated or irritable mood lasting at least with manic symptoms. Causes observable functional changes but does not require hospitalization or produce psychotic features.
2. Nursing Management of Acute Mania
Safety & Physiological Needs (Highest Priority):
Provide high-calorie finger foods, frequent water/hydration, structured rest periods, and a low-stimulation environment.
Behavioral Control & Communication:
Use calm, firm, assertive directives for limit-setting regarding impulsive or inappropriate behaviors.
If limit-setting is ineffective, redirect energy into healthy, structured physical outlets.
Do not argue with or validate grandiose delusions; connect to underlying emotions.
3. Mood Stabilizers & Laboratory Monitoring
Lithium Carbonate (Lithobid):
Therapeutic Window: . Renal metabolism (monitor BUN and Serum Creatinine).
Mechanism & Fluid Dynamics: Replaces sodium () ions and inhibits ADH, leading to diuresis and thirst.
Patient Teaching: Drink of water daily. Maintain consistent dietary sodium and caffeine intake (sudden sodium drops cause lithium level spikes; increased caffeine lowers levels). Take with meals to reduce GI upset.
Toxicity Signs: Nausea, vomiting, severe diarrhea, coarse hand tremor, ataxic gait, nystagmus, dysarthria, renal impairment, seizures, coma.
Anticonvulsant Mood Stabilizers:
Valproic Acid (Depakote): Teratogenic (black box warning for neural tube defects); requires LFT monitoring (AST, ALT).
Carbamazepine (Tegretol) & Lamotrigine (Lamictal): High risk for Stevens-Johnson Syndrome (SJS), a toxic skin emergency marked by fever, blistering rash, and mucous membrane lesions. Hold medication and report immediately.
Phenytoin (Dilantin): Therapeutic range . Side effects include gingival hyperplasia requiring routine dental hygiene.
4. Suicide Assessment & Crisis De-escalation
ASQ Screening Tool Routine:
Direct assessment questions (e.g., current suicidal intent).
Answering "Yes" to acute intent requires immediate action: stay with the patient, remove lethal objects, notify provider, and initiate an urgent mental health evaluation STAT.
De-escalation Strategies:
Maintain a calm, non-reactive presence; build rapport using active, reflective listening.
Use collaborative problem-solving and establish a concrete safety plan for continuity of care.
Apply legal and ethical principles including duty to protect, least restrictive measures, and thorough documentation.